United Therapeutics (UTHR) Cash from Operations (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Cash from Operations data on file, last reported at 463300000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations changed 0.46% year-over-year to 463300000.0; the trailing twelve-month figure through Mar 2026 stood at 1563300000.0 (up 10.73% YoY), and the FY2025 full-year result was 1561200000.0, up 17.64% from the prior year.
• Cash from Operations rose to 463300000.0 in Q1 2026, from 346200000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 562100000.0 in Q3 2025 to a low of 106300000.0 in Q2 2023.
• A 5-year average of 301888235.29 and a median of 341200000.0 in 2024 frame the typical range for Cash from Operations.
• Peak annual rise in Cash from Operations reached 221.49% in 2022, while the deepest fall reached 26.58% in 2022.
• Tracing UTHR's Cash from Operations over 5 years: stood at 128200000.0 in 2022, then increased by 17.55% to 150700000.0 in 2023, then surged by 126.41% to 341200000.0 in 2024, then gained by 1.47% to 346200000.0 in 2025, then surged by 33.82% to 463300000.0 in 2026.
• Business Quant data shows UTHR's Cash from Operations at 463300000.0 in Q1 2026, 346200000.0 in Q4 2025, and 562100000.0 in Q3 2025.